Low cost digital patholgy to predict ER positive breast cancer

Digital Pathology based low-cost outcome predictor for ER positive Breast Cancers

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

CTRI

Registry ID

CTRI/2020/06/025606

Enrollment

250

Registered

2020-06-04

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: Tissue Blocks of Breast Cancer patients

Exclusion criteria

Exclusion criteria: NIl

Design outcomes

Primary

Measure	Time frame
Develop and optimize an Image-Based Risk Score (Ibris) for identifying Indian patients with ER+ breast cancer who will not benefit from chemotherapyTimepoint: During the study period	—

Secondary

Measure	Time frame
Quantitatively evaluate Ibris performance on an independent test set to identify those ER positive breast cancer patients who will respond well to hormonal therapy aloneTimepoint: During the study period	—

Countries

India

Contacts

Public ContactShabina Siddique

Tata Memorial Centre

vaniparmar@gmail.com02224177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026